Fig. 3: Subgroup analyses of progression-free survival in the efficacy-evaluable population. | Blood Cancer Journal

Fig. 3: Subgroup analyses of progression-free survival in the efficacy-evaluable population.

From: Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma

Fig. 3

Survival curves are stratified by: A pathological types, B double-expression lymphoma status, C IELSG prognostic score group, D MSKCC prognostic score group, E diagnostic modality, and F receipt of ASCT consolidation therapy. Note: PFS in panel (F) is defined as the time from the initiation of either ASCT consolidation or orelabrutinib maintenance therapy to disease relapse/progression or death from any cause, whichever occurs first. GCB germinal center B-cell-like, DLBCL diffuse large B-cell lymphoma, PFS progression-free survival, IELSG International Extranodal Lymphoma Study Group, MSKCC Memorial Sloan-Kettering Cancer Center, ASCT autologous hematopoietic stem cell transplantation.

Back to article page